Pozen to Present at UBS Global Life Sciences Conference
Posted on: Tuesday, 13 September 2005, 09:01 CDT
POZEN Inc. (NASDAQ: POZN) announced today that John R. Plachetka, Pharm.D., the company's chairman, president and chief executive officer, will be speaking to investors at the UBS Global Life Sciences Conference on Tuesday, September 27, 2005 at 10:30 a.m. Eastern Time in New York City. Dr. Plachetka's presentation will be webcast and archived on POZEN's home page at www.pozen.com.
POZEN is a pharmaceutical company committed to developing therapeutic advancements for diseases with unmet medical needs where it can improve efficacy, safety, and/or patient convenience. Since its inception, POZEN has focused its efforts primarily on the development of pharmaceutical products for the treatment of migraine. POZEN is also exploring the development of product candidates in other pain-related therapeutic areas. POZEN has development and commercial alliances with GlaxoSmithKline, Valeant Pharmaceuticals North America, a subsidiary of Valeant Pharmaceuticals International (formerly Xcel Pharmaceuticals, Inc.), and Nycomed Danmark ApS. The company's common stock is traded on The Nasdaq Stock Market under the symbol "POZN". For detailed company information, including copies of this and other press releases, see POZEN's website: www.pozen.com.
Source: Business Wire
Related Articles
- Progress made toward smallpox medication
- Magen BioSciences Licenses Dermatology Assets From Lilly
- Biothera to Present Cancer Immunotherapy Research at BIO International Convention
- POZEN To Present at the 2007 UBS Global Generic and Specialty Pharmaceuticals Conference
- BioSante Pharmaceuticals Reports Product Development Highlights and Financial Results for 2005
- Amylin Inc. Selects Site to Develop $150M Plant
- BioSante Pharmaceuticals Reports Product Development Highlights and Third Quarter 2005 Financial Results
- BioSante Pharmaceuticals Reports Product Development Highlights and Second Quarter 2005 Financial Results
- Silver Spring-Based United Therapeutics Corp. Reports Rise in Second- Quarter Net Income
- Xanodyne Developing Pharmaceutical First For Women's Health
User Comments (0)

RSS Feeds